Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma.
Iiyama T, Udaka K, Takeda S, Takeuchi T, Adachi YC, Ohtsuki Y, Tsuboi A, Nakatsuka S, Elisseeva OA, Oji Y, Kawakami M, Nakajima H, Nishida S, Shirakata T, Oka Y, Shuin T, Sugiyama H. Iiyama T, et al. Among authors: shirakata t. Microbiol Immunol. 2007;51(5):519-30. doi: 10.1111/j.1348-0421.2007.tb03940.x. Microbiol Immunol. 2007. PMID: 17579261 Free article. Clinical Trial.
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, Hosen N, Yoshihara S, Wu F, Fujiki F, Murakami M, Masuda T, Nishida S, Shirakata T, Nakatsuka S, Sasaki A, Udaka K, Dohy H, Aozasa K, Noguchi S, Kawase I, Sugiyama H. Oka Y, et al. Among authors: shirakata t. Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90. doi: 10.1073/pnas.0405884101. Epub 2004 Sep 13. Proc Natl Acad Sci U S A. 2004. PMID: 15365188 Free PMC article. Clinical Trial.
Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.
Tsuboi A, Oka Y, Nakajima H, Fukuda Y, Elisseeva OA, Yoshihara S, Hosen N, Ogata A, Kito K, Fujiki F, Nishida S, Shirakata T, Ohno S, Yasukawa M, Oji Y, Kawakami M, Morita S, Sakamoto J, Udaka K, Kawase I, Sugiyama H. Tsuboi A, et al. Among authors: shirakata t. Int J Hematol. 2007 Dec;86(5):414-7. doi: 10.1007/BF02983998. Int J Hematol. 2007. PMID: 18192109
Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.
Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, Hashimoto N, Maruno M, Elisseeva OA, Shirakata T, Kawakami M, Oji Y, Nishida S, Ohno S, Kawase I, Hatazawa J, Nakatsuka S, Aozasa K, Morita S, Sakamoto J, Sugiyama H, Yoshimine T. Izumoto S, et al. Among authors: shirakata t. J Neurosurg. 2008 May;108(5):963-71. doi: 10.3171/JNS/2008/108/5/0963. J Neurosurg. 2008. PMID: 18447714 Clinical Trial.
Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
Li Z, Oka Y, Tsuboi A, Fujiki F, Harada Y, Nakajima H, Masuda T, Fukuda Y, Kawakatsu M, Morimoto S, Katagiri T, Tatsumi N, Hosen N, Shirakata T, Nishida S, Kawakami Y, Udaka K, Kawase I, Oji Y, Sugiyama H. Li Z, et al. Among authors: shirakata t. Microbiol Immunol. 2008 Nov;52(11):551-8. doi: 10.1111/j.1348-0421.2008.00069.x. Microbiol Immunol. 2008. PMID: 19090835 Free article.
A WT1 protein-derived, naturally processed 16-mer peptide, WT1(332), is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4(+) T cells.
Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Nakajima H, Elisseeva OA, Harada Y, Li Z, Tatsumi N, Kamino E, Shirakata T, Nishida S, Taniguchi Y, Kawase I, Oji Y, Sugiyama H. Fujiki F, et al. Among authors: shirakata t. Microbiol Immunol. 2008 Dec;52(12):591-600. doi: 10.1111/j.1348-0421.2008.00080.x. Microbiol Immunol. 2008. PMID: 19120973 Free article.
Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration.
Nakajima H, Oka Y, Tsuboi A, Tatsumi N, Yamamoto Y, Fujiki F, Li Z, Murao A, Morimoto S, Hosen N, Shirakata T, Nishida S, Kawase I, Isaka Y, Oji Y, Sugiyama H. Nakajima H, et al. Among authors: shirakata t. Vaccine. 2012 Jan 17;30(4):722-9. doi: 10.1016/j.vaccine.2011.11.074. Epub 2011 Nov 29. Vaccine. 2012. PMID: 22133512
Overexpression of the Wilms' tumor gene WT1 in esophageal cancer.
Oji Y, Yano M, Nakano Y, Abeno S, Nakatsuka S, Ikeba A, Yasuda T, Fujiwara Y, Takiguchi S, Yamamoto H, Fujita S, Kanato K, Ito K, Jomgeow T, Kawakami M, Tsuboi A, Shirakata T, Nishida S, Hosen N, Oka Y, Aozasa K, Monden M, Sugiyama H. Oji Y, et al. Among authors: shirakata t. Anticancer Res. 2004 Sep-Oct;24(5B):3103-8. Anticancer Res. 2004. PMID: 15510596 Free article.
A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.
Morita S, Oka Y, Tsuboi A, Kawakami M, Maruno M, Izumoto S, Osaki T, Taguchi T, Ueda T, Myoui A, Nishida S, Shirakata T, Ohno S, Oji Y, Aozasa K, Hatazawa J, Udaka K, Yoshikawa H, Yoshimine T, Noguchi S, Kawase I, Nakatsuka S, Sugiyama H, Sakamoto J. Morita S, et al. Among authors: shirakata t. Jpn J Clin Oncol. 2006 Apr;36(4):231-6. doi: 10.1093/jjco/hyl005. Epub 2006 Apr 12. Jpn J Clin Oncol. 2006. PMID: 16611662 Clinical Trial.
Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro.
Jomgeow T, Oji Y, Tsuji N, Ikeda Y, Ito K, Tsuda A, Nakazawa T, Tatsumi N, Sakaguchi N, Takashima S, Shirakata T, Nishida S, Hosen N, Kawakami M, Tsuboi A, Oka Y, Itoh K, Sugiyama H. Jomgeow T, et al. Among authors: shirakata t. Cancer Sci. 2006 Apr;97(4):259-70. doi: 10.1111/j.1349-7006.2006.00169.x. Cancer Sci. 2006. PMID: 16630117 Free PMC article.
46 results